Stories
Stories
Innovation as Antidote
Illustration by Andrea Manzati
You'll see a theme emerge in this issue's stories on health care: The industry has a number of deep-seated challenges that it is just beginning to face. It's a pen-and-paper operation in a digital world. It struggles with inefficiency while working for a clientele that can't afford any lost time. You know—the perfect kind of challenge for the HBS community.
Last year, HBS and Harvard Medical School's Forum on Healthcare Innovation brought together everyone from biotech execs to policymakers in an effort to spur innovation. With input from more than 200 industry leaders and academics, the forum identified a number of important challenges, and offered five "key imperatives" for progress—from making value the central objective to decentralizing care delivery.
Several HBS alumni and faculty members are also leading efforts that provide prescriptions for what ails the industry ("Curing Health Care"), including Halle Tecco's (MBA 2011) focus on incubating new ideas and Gregory Stock's (MBA 1987) push to make medicine more personalized.
WILLIAMS
Photo by Mark Ostow
The energy behind these ideas originates in the HBS community's desire to fix intractable problems. But the inspiration typically comes from a very human place. DART Therapeutics CEO Gene Williams (MBA 1987) ("Your Own Medicine"), for instance, told us about a revelation he had during a 2002 trip to Rotterdam to observe clinical trials for the first-ever Pompe disease treatment, which was pushed forward by John Crowley (MBA 1997), whose son and daughter suffer from the rare, often fatal neuromuscular disorder.
Williams, then working for Genzyme, was walking around a hospital with the trial's investigators and came upon a group of patients who looked about five years old—much older than the infants he was expecting. "And it hit me like a bolt of lightning," Williams said. "They're five years old! They would have been dead two years ago without the therapy we were working on, no question about it—absolutely none."
What it took—both in that case and in all the examples in this issue—was a new idea, a new way of thinking. Sometimes, it seems, that can be the best medicine.
—THE EDITORS
Post a Comment
Related Stories
-
- 28 Apr 2016
- HBS Alumni News
New Venture Competition Winners Announced
Re: Peter Park (MBA 2008); Jodi Gernon (MBA 1991); Jeff Sandefer (MBA 1986) -
- 01 Jun 2014
- HBS Alumni Bulletin
Alumni and Faculty Books for June 2014
Re: Johanne Lavoie (MBA 1993); Stan Beck (PMD 64); Jonathan Bush (MBA 1997); Gina Carr (MBA 1990); Alistair Davidson (MBA 1976); Jacques De Guerny (AMP 82); May Chao (MBA 1985); Scott Gillis (MBA 1988); Helmut Horchler (AMP 100); Scott Kyle (MBA 1993); Gerry Langeler (MBA 1977); Mal Mixon (MBA 1968); Tracy Morgan (MBA 1990); George Moseley (MBA 1965); Bozidar Novak (OPM 43); Grace Reinbold (OPM 7); Marty Shapiro (MBA 1966); Gil Tostengard (MBA 1953); Bernie White (MBA 1971); Mike Morris (MBA 1972); Dev Barker (PMD 23); Amy C. Edmondson (Novartis Professor of Leadership and Management); Linda A. Hill (Wallace Brett Donham Professor of Business Administration); Sophus A. Reinert (T.J. Dermot Dunphy Professor of Business Administration); Frank V. Cespedes (MBA Class of 1973 Senior Lecturer of Business Administration) -
- 01 Jun 2014
- HBS Alumni Bulletin
Feedback
Re: Peter Doering (MBA 1987); Roger Cole (MBA 1985); Gordon Johnson (MBA 1950); Fred Brodsky (OPM 27); George Baker (MBA 2008); Frank Blethen (PMD 35); Ken Workman (PMD 35) -
- 01 Jun 2014
- HBS Alumni Bulletin
Spring Training for Startups
Re: Sheila Marcelo (MBA 1998); Angie Hicks (MBA 2000)
